Stay updated with breaking news from Oraquick Ebola. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
OraSure Technologies (NASDAQ:OSUR – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a report released on Wednesday. Separately, Evercore ISI cut their target price on shares of OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating on the stock in a report on Thursday, April […]
StockNews.com upgraded shares of OraSure Technologies (NASDAQ:OSUR – Free Report) from a hold rating to a buy rating in a report issued on Wednesday. Separately, Evercore ISI cut their price target on shares of OraSure Technologies from $7.00 to $6.50 and set an in-line rating on the stock in a report on Thursday, April 4th. […]
OraSure Technologies (NASDAQ:OSUR – Get Free Report) and IceCure Medical (NASDAQ:ICCM – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk. Valuation & Earnings This table compares OraSure […]
OraSure Technologies (Nasdaq:OSUR) announced today that received a government contract to develop a second-generation Ebola diagnostic.
The firm will update its Ebola rapid antigen test that was authorized by the US Food and Drug Administration in 2019.